Iovance Biotherapeutics Inc (IOVA) (Q3 2026) Earnings Call Highlights: Record $122 Million ... - Yahoo Finance
Yahoo Finance · Nov 6, 11:10 AM
Iovance Biotherapeutics (IOVA) Lifileucel Wins Fast Track After Strong Sarcoma Trial Data - Yahoo Finance
Yahoo Finance · Nov 5, 10:16 PM
Iovance Biotherapeutics: Q3 Earnings Snapshot - Yahoo Finance
Yahoo Finance · Nov 5, 12:10 PM
Market reactionShares fell 11% on Nov 5.
Iovance is a commercial-stage cell therapy company. Its lead product, Amtagvi (lifileucel), is approved for advanced melanoma; Iovance plans to seek approval in non-small cell lung cancer, with a filing planned for 2027.
Amtagvi's approved melanoma business has demonstrated adoption through rising sales, broader access and manufacturing improvements. Raised revenue guidance supports growth, while management expects current cash to fund operations into 2H28. Lung cancer is the larger opportunity, and the case for it has weakened. The response rate held at 24.6% across 69 patients, but 13 of the 17 responses came from a 22-patient subgroup identified after the fact. Iovance is adding a biomarker-selected registrational cohort, and the broad 2027 filing still depends on FDA discussions.
Thesis checklist
1 risk needs attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: IOV-LUN-202 supports the planned NSCLC filing
Do final broader-population responses, durability, safety and FDA feedback support the planned NSCLC filing?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Lung data hold near 25% as Iovance shifts toward a biomarker-selected group
Lung data hold near 25% as Iovance shifts toward a biomarker-selected group
First approved TIL therapy scaling toward NSCLC and sarcoma, with confirmatory Phase 3 data the pivot from accelerated to full approval
First approved TIL therapy for solid tumors building toward frontline melanoma, contingent on TILVANCE-301 converting early combination signals into a Phase 3 win
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Drug pages: Lifileucel
Disease areas: Lung cancer, Breast and gynecologic cancers, Other cancers
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
12 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.